Grant: Project Grant
McGill University
$459,000.00
Analgesic mechanisms of melatonin MT2 receptor ligands.
FY 2016-17
Summary
Neuropathic pain (NP) is a chronic disorder characterized by severe and chronic pain. 56% of Canadians have experienced moderate-to-severe pain in the past 3 months and Canada spends about $6 billion/year for NP treatment. Therapeutics for NP are scant; international guidelines recommend gabapentine, pregabalin and/or antidepressants, and as a second line opioids; however, all these drugs have partial efficacy and induce severe side effects, including addiction liability. The goal of this project is to demonstrate that novel selective melatonin MT2 receptor (MT2) agonists alleviate pain by interacting with opioid receptor and activating specific intracellular pathways. Ultimately, the goal of this project is to elucidate the mechanism of action of MT2 agonists as analgesics and to demonstrate that they can be a safer alternative to opioids.
Department
Program
Project Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
357059
Name
Gobbi Gabriella
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Analgesic mechanisms of melatonin MT2 receptor ligands.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$459,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Electrophysiology; Gpcr; Melatonin; Molecular Biology; Mt2 Receptor; Neuropathic Pain; Pain
Abstract
Neuropathic pain (NP) is a chronic disorder characterized by severe and chronic pain. 56% of Canadians have experienced moderate-to-severe pain in the past 3 months and Canada spends about $6 billion/year for NP treatment. Therapeutics for NP are scant; international guidelines recommend gabapentine, pregabalin and/or antidepressants, and as a second line opioids; however, all these drugs have partial efficacy and induce severe side effects, including addiction liability. The goal of this project is to demonstrate that novel selective melatonin MT2 receptor (MT2) agonists alleviate pain by interacting with opioid receptor and activating specific intracellular pathways. Ultimately, the goal of this project is to elucidate the mechanism of action of MT2 agonists as analgesics and to demonstrate that they can be a safer alternative to opioids.
Competitiondate
201610
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Gobbi, Gabriella
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $459,000~ $0~
